Elegent Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 15-07-2024
- Paid Up Capital ₹ 4.39 Cr
as on 15-07-2024
- Company Age 34 Year, 5 Months
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 20.51 Cr
as on 15-07-2024
- Revenue %
(FY 2016)
- Ebitda
- Net Worth -0.00%
(FY 2016)
- Total Assets %
(FY 2016)
About Elegent Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 4.39 Cr.
The company currently has active open charges totaling ₹20.51 Cr.
Dhirendra Sanghavi, Manjula Sanghavi, and Tejas Desai serve as directors at the Company.
- CIN/LLPIN
L24239MH1990PLC057214
- Company No.
057214
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Jul 1990
- Date of AGM
30 Sep 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Elegent Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhirendra Sanghavi  | Managing Director | 23-Mar-1992 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manjula Sanghavi | Additional Director | 29-Nov-2018 | Current |
| Tejas Desai | Additional Director | 29-Nov-2018 | Current |
Financial Performance of Elegent Pharmaceuticals.
Elegent Pharmaceuticals Limited, for the financial year ended 2016, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Elegent Pharmaceuticals?
Unlock access to Elegent Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 09 Feb 1996 | ₹5.00 M | Open |
Bank Of Baroda Creation Date: 30 Jun 1995 | ₹1.50 Cr | Open |
Bank Of Baroda Creation Date: 25 Feb 1995 | ₹5.00 M | Open |
How Many Employees Work at Elegent Pharmaceuticals?
Unlock and access historical data on people associated with Elegent Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elegent Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elegent Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
